Newly launched PAXgene Saliva Collector stabilizes collected sample to avoid preanalytical errors and thereby increases reproducibility and reliability of results
QIAreach SARS-CoV-2 Antigen Test, developed in collaboration with Ellume, provides accurate and objective results in 2 to 15 minutes
Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases
Solutions combine liquid-based sample preparation with PCR detection and Sanger sequencing
Digital PCR for COVID-19 wastewater testing overcomes limitations of traditional PCR
QIAstat-Dx and NeuMoDx tests continue to detect all known viral variants extremely effectively
Test adds to QIAGEN’s growing portfolio of PCR testing solutions for COVID-19 testing
QIAreach SARS-CoV-2 Antigen Test is an important step towards decentralized mass screening by processing samples in 2–15 minutes
Menu of test solutions for infectious diseases – which already includes COVID-19 – to be expanded, especially in the U.S.
Access Anti-SARS-CoV-2 Antigen Test, developed in collaboration with Ellume, aims to provide accurate results in less than 15 minutes
QIAseq SARS-CoV-2 Primer Panel converts viral RNA samples into libraries ready for sequencing, whereas QIAGEN Digital Insights solutions support COVID-19 drug, vaccine and epidemiology research
Access Anti-SARS-CoV-2 is an easy-to-use 10-minute test on a portable device that provides highly accurate results on total Ig antibodies
The test kit aims to differentiate novel coronavirus from 21 other pathogens implicated in respiratory syndromes
QIAGEN launches therascreen PIK3CA RGQ PCR Kit in Europe
Japan selects QIAGEN Clinical Insight-Interpret to handle next-generation sequencing data
Agreement adds commercial firepower for QIAGEN’s U.S. launch of the next-generation platform for syndromic insights initially for respiratory conditions
